Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Claire Leve

Obstetrics & Gynecology Nevada City, CA Medical Doctor

NPI 1174558027 CMS profile 396497

15301 Tyler Foote Rd, Nevada City, CA 95959

Open in the dashboard

General payments

$571

24 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Claire Leve of Nevada City, CA is reported in the CMS Open Payments database as having received $571 across 24 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $74 4
2023 General $101 5
2022 General $118 6
2021 General $205 5
2020 General $35 2
2019 General $37 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Claire Leve
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Claire Leve were reported at $74. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Claire Leve Obstetrics & Gynecology median Middle half National median
2019 $37 $172 $62–$391 $163
2020 $35 $94 $36–$222 $114
2021 $205 $136 $42–$369 $132
2022 $118 $160 $50–$433 $149
2023 $101 $169 $56–$423 $160
2024 $0 $152 $50–$371 $164
2025 $74 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $173 4 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $120 5 payments
  3. Exact Sciences Corporation $60 3 payments
  4. Pfizer Inc. $60 3 payments
  5. Lilly USA, LLC $37 2 payments
  6. Novartis Pharmaceuticals Corporation $21 1 payment
  7. AstraZeneca Pharmaceuticals LP $21 1 payment
  8. Hologic, LLC $19 1 payment
  9. Actelion Pharmaceuticals US, Inc. $18 1 payment
  10. Janssen Pharmaceuticals, Inc $15 1 payment
  11. Other $28 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $571 24 payments
Products named General payments · program years 2019–2025
  1. RYBELSUS $173 4 payments
  2. JARDIANCE $120 5 payments
  3. Ozempic $53 3 payments
  4. Cologuard Collection Kit $38 2 payments
  5. ZEPBOUND $37 2 payments
  6. PREVNAR 20 $28 1 payment
  7. COMIRNATY $28 1 payment
  8. The Cologuard Plus Collection Kit $22 1 payment
  9. LEQVIO $21 1 payment
  10. ENTRESTO $21 1 payment
  11. Other $233 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

231

Median for Obstetrics & Gynecology: 65

Drug cost

$3,606

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

7.4%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Levothyroxine Sodium Generic 40 $1,074
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 17 $443
Losartan Potassium Generic 23 $321
Atorvastatin Calcium Generic 22 $279
Metformin Hcl Generic 15 $238
Simvastatin Generic 18 $233
Rosuvastatin Calcium Generic 13 $214
Trazodone Hcl Generic 12 $200
Amlodipine Besylate Generic 23 $177
Lisinopril Generic 26 $149

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Records

24 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record